Login to Your Account



COI Fishing for More Start-ups

Wheat Beat: Celiac Firm Sitari Reaps $10M From GSK, Avalon

By Randy Osborne
Staff Writer

Thursday, November 21, 2013
financings_resized.jpg

First to benefit from a deal between Glaxosmithkline plc (GSK) and Avalon Ventures that will launch as many as 10 new companies is Sitari Pharmaceuticals Inc., funded with $10 million in Series A money to pursue early work targeting the transglutaminase 2 (TG2) pathway.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription